WIZBIOTECH Highlights Fecal Calprotectin Testing and Gut Health Solutions at 2025 China Geriatric Laboratory Medicine Conference
Recently, the 2nd Annual Meeting of the Laboratory Medicine Committee of the China Association of Gerontology and Geriatrics and the 2025 China Conference on High-Quality Development in Geriatric Laboratory Medicine concluded successfully. The conference focused on cutting-edge technologies and future trends in geriatric laboratory medicine, bringing together leading experts, scholars, and industry representatives to explore new strategies and technologies for elderly health management.
As a high-tech enterprise specializing in in-vitro diagnostics (IVD), WIZBIOTECH was invited to participate and showcased a range of innovative products and solutions.
Focus on Gut Health Solutions for the Elderly
During the conference, WIZBIOTECH highlighted its core diagnostic solutions in gut health management quantitative fecal calprotectin testing and quantitative fecal occult blood testing.
These two tests address the high prevalence of intestinal inflammation and tumor risk among the elderly, offering efficient, non-invasive screening tools that drew wide attention from attending experts and clinicians.
Fecal calprotectin quantitative testing provides a reliable biomarker for the diagnosis and monitoring of inflammatory bowel disease (IBD). By measuring calprotectin levels in stool, the test objectively reflects the degree of intestinal inflammation, assisting physicians in evaluating IBD activity. This is particularly valuable for elderly patients who require long-term, dynamic disease management.
Dual-Target Screening: Calprotectin + Fecal Occult Blood
To further enhance early detection of colorectal cancer, WIZBIOTECH introduced an innovative dual-quantitative screening approach that combines fecal calprotectin with fecal occult blood testing.
While fecal occult blood testing has long been a standard marker for colorectal cancer screening, it suffers from false positives and false negatives.
When combined with calprotectin testing, clinicians can simultaneously assess inflammation and bleeding, significantly improving the detection rate of colorectal cancer and precancerous lesions, while reducing missed diagnoses.
This integrated approach provides elderly populations with a more comprehensive, reliable, and non-invasive pathway for intestinal health screening.
Addressing the Challenges of an Aging Society
With China's aging population accelerating, elderly health issues are receiving unprecedented attention. Seniors are at higher risk of gastrointestinal diseases such as IBD and colorectal cancer, yet clinical diagnosis and early detection remain challenging due to atypical symptoms and multiple comorbidities.
Calprotectin testing—alone or in combination with occult blood testing—offers a sensitive, convenient, and patient-friendly solution ideally suited for elderly intestinal disease screening and long-term health management.
Expert Recognition and Industry Collaboration
At the exhibition, WIZBIOTECH's team engaged in in-depth discussions with laboratory physicians, clinical experts, and scholars from across the country. Many experts emphasized that calprotectin testing and the combined dual-screening approach hold great promise for elderly populations and could become an essential component of routine health check-ups and chronic disease management in the future.
Commitment to Innovation and Elderly Health
Looking ahead, WIZBIOTECH will continue to uphold its mission of "Advancing diagnostic technology to improve quality of life." The company remains committed to innovation in the IVD field, accelerating the clinical translation and application of new technologies. By providing more precise, convenient, and reliable diagnostic solutions, WIZBIOTECH aims to contribute to elderly health management and support the realization of the Healthy China 2030 strategic goals.
